AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25740805
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% voriconazole
Trial: 15262190
Drug: EPA-rich oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-rich oil (9 g oil/day for 4 weeks)
Trial: 15262190
Drug: DHA-rich oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich oil (9 g oil/day for 4 weeks)
Trial: 15262190
Drug: Placebo (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olive oil, 9 g oil/day for 4 weeks)
Trial: 11289288
Drug: Topical 0.3
RxNorm normalized name: triclosan topical 0.3% topical bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.3 percent nifedipine and 1.5 percent lidocaine ointment every 12 hours for two weeks
Trial: 11289288
Drug: Topical 1.5
RxNorm normalized name: phenol topical 1.5% topical liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.5 percent lidocaine ointment
Trial: 9879778
Drug: Paclitaxel 210
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression
Trial: 6102797
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or low dosages of antipsychotics (PLD)
Trial: 6102797
Drug: High conventional
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High conventional dosages of antipsychotics (HCD)
Trial: 27011294
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg fish oil supplements daily containing 120 mg DHA and 180 mg EPA
Trial: 23196671
Drug: Hass avocado
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hass avocado (68 g) with hamburger
Trial: 23196671
Drug: Hamburger alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hamburger alone (250 g)
Trial: 12547847
Drug: Acarbose (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (titrated up to 100 mg b.i.d.)
Trial: 11180022
Drug: Cetrorelix 1
RxNorm normalized name: cetrorelix 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 1 mg
Trial: 11180022
Drug: Cetrorelix 3
RxNorm normalized name: cetrorelix 3 mg subcutaneous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix 3 mg
Trial: 11180022
Drug: Cetrorelix 5
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix 5 mg
Trial: 1726004
Drug: Lacidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4 to 6 mg once daily)
Trial: 1726004
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 to 50 mg once daily)
Trial: 6354408
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base and metronidazole (oral)
Trial: 26908016
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies involving drug discontinuation only (37%)
Trial: 26908016
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies involving drug discontinuation with transfusion of red cell concentrates (38%)
Trial: 26908016
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies involving drug discontinuation with transfusion of plasma (23%)
Trial: 26908016
Drug: Warfarin management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin management
Trial: 22885247
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg THC
Trial: 22885247
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg THC
Trial: 22885247
Drug: THC (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (all doses)
Trial: 6342643
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 100 micrograms
Trial: 6342643
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (various doses)
Trial: 27098817
Drug: CET as
RxNorm normalized name: CET
DrugBank: Cefalotin (DB00456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CET as group therapy
Trial: 20386062
Drug: Creative arts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative arts therapy (CAT)
Trial: 18714203
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (body stroking and passive limb movements for three, 15-minute periods per day for 5 days)
Trial: 18714203
Drug: Standard nursery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nursery care without massage therapy
Trial: 10408495
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy with cyclophosphamide, methotrexate, and fluorouracil
Trial: 8911372
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine dermal patches postauricularly
Trial: 1875230
Drug: Cefotetan (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (total dose, 20 g)
Trial: 1875230
Drug: Clindamycin (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (total dose, 12 g) plus Amikacin (total dose, 5 g)
Trial: 6897369
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide) with delays of less than 10 weeks
Trial: 6897369
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (FAC) with delays of 10-13 weeks
Trial: 6897369
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (FAC) with delays of 14-17 weeks
Trial: 6897369
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (FAC) with delays of greater than or equal to 18 weeks
Trial: 29921393
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block (cFNB) with 0.375% ropivacaine hydrochloride, 20 mL loading dose
Trial: 29921393
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) with fentanyl, 0.05 mg loading dose
Trial: 24025033
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy combined with functional strength training
Trial: 24025033
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy combined with movement performance therapy
Trial: 12226016
Drug: Salmeterol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (25 micro g, two puffs bid for 6 weeks)
Trial: 9513753
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic hormone (ANH)
Trial: 2518874
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg o.m.
Trial: 21748770
Drug: Rosiglitazone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone alone (4 mg twice-daily)
Trial: 21748770
Drug: Rosiglitazone and
RxNorm normalized name: Rosiglitazone and Glimepiride Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone and metformin (4 mg rosiglitazone and 500 mg metformin twice-daily)
Trial: 21748770
Drug: Rosiglitazone and
RxNorm normalized name: Rosiglitazone and Glimepiride Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone and losartan (4 mg rosiglitazone and 50 mg losartan once-daily)
Trial: 14625121
Drug: Oral 17beta‐E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17beta‐E2 + NETA for 3 months
Trial: 14625121
Drug: Transdermal 17beta‐E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐E2 + MPA for 3 months
Trial: 14625121
Drug: Transdermal 17beta‐E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐E2 + MPA for 12 months
Trial: 1593561
Drug: Hygroscopic cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hygroscopic cervical dilators and Intracervical prostaglandin E2 (PGE2) gel
Trial: 2934579
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with flutamide and LHRH agonist (or orchiectomy)
Trial: 31439956
Drug: Steroids (n=77)
RxNorm normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (n=77)
Trial: 25352732
Drug: Four tablets
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tablets at full dose
Trial: 25352732
Drug: Two softgels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two softgels at full dose
Trial: 25352732
Drug: One softgel
RxNorm normalized name: Stuart One Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One softgel at half-dose
Trial: 25352732
Drug: Zinc absorption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc absorption
Trial: 22967121
Drug: Levofloxacin/amoxicillin/esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin/amoxicillin/esomeprazole
Trial: 9150331
Drug: Hospital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital therapy
Trial: 8398529
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and droperidol
Trial: 2943643
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin K 2165
Trial: 26547291
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg biweekly (Q2W) or 420 mg monthly (QM)
Trial: 24767519
Drug: Protocol-directed physical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-directed physical therapy (pdPT)
Trial: 24767519
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (ST)
Trial: 18480036
Drug: Percentage format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage format (e.g., 12%)
Trial: 18480036
Drug: Frequency format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency format (e.g., 12 in 100)
Trial: 18480036
Drug: 1-in-n format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-in-n format (e.g., 1 in 8)
Trial: 15900006
Drug: Meta-analyses (limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analyses (limited to studies addressing treatment effects)
Trial: 10029478
Drug: Subperiosteal nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subperiosteal nasal floor augmentation with Surgicel
Trial: 8659717
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg/mL
Trial: 8659717
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg/mL plus lidocaine 10 mg/mL
Trial: 8659717
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg/mL plus lidocaine 20 mg/mL
Trial: 1794158
Drug: Clomipramine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 150 mg/day administered at noon
Trial: 1794158
Drug: Clomipramine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 150 mg/day administered at morning or before bedtime
Trial: 1794158
Drug: Clomipramine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine administered three times a day by traditional, equally divided doses
Trial: 6363078
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg (N10)
Trial: 6363078
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg (N20)
Trial: 26922537
Drug: Atorvastatin 40mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg/d
Trial: 26922537
Drug: Atorvastatin 40mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg/d + Ezetimibe 10mg/d
Trial: 23668824
Drug: Triclosan-containing toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclosan-containing toothpaste (3000 μg/mL TCS)
Trial: 17406798
Drug: Paclitaxel-containing radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel-containing radiochemotherapy (paclitaxel 25-35 mg/m² twice weekly)
Trial: 17406798
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment administered to a total dose of 45-60 Gy
Trial: 14695786
Drug: PEG‐IFN (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN (0.5 microg/body weight/week) and ribavirin (1,000 mg-1,200 mg/daily) for 48 weeks
Trial: 9208361
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg) administered alone
Trial: 9208361
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg) administered after ranitidine treatment
Trial: 9208361
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg) with cola beverage
Trial: 9208361
Drug: Ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine treatment (gastric pH at least 6.0)
Trial: 8119049
Drug: Theophylline target
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline target concentration of 10 mg/L
Trial: 8119049
Drug: Theophylline target
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline target concentration of 20 mg/L
Trial: 23881309
Drug: internet-delivered acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered acceptance and commitment therapy (iACT)
Trial: 23237436
Drug: ω-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 PUFA treatment (1 g/day for 6 months)
Trial: 20354834
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg d(‐1) for 8 days prior to exercise trial and 600 mg on the day of exercise trial
Trial: 18622600
Drug: Brain natriuretic
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain natriuretic peptide (BNP) infusion at 16.2 pmol/min for 30 min
Trial: 18622600
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion at 16.2 pmol/min for 30 min
Trial: 12598065
Drug: Ximelagatran (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (15, 30 or 60 mg)
Trial: 12598065
Drug: r-hirudin (intravenous)
RxNorm normalized name: R-hirudin
DrugBank: Lepirudin (DB00001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: r-hirudin (intravenous)
Trial: 12598065
Drug: Enoxaparin (subcutaneous)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (subcutaneous)
Trial: 12851531
Drug: Ximelagatran (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (60 mg)
Trial: 9708720
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 0.050% nasal spray, 50 microg, 4 times daily for 2 weeks
Trial: 9708720
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate 0.075% nasal spray, 75 microg, 4 times daily for 2 weeks
Trial: 359398
Drug: Atenolol (ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (ICI 66082) 100 mg daily for 30 days
Trial: 359398
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 30 days
Trial: 28510350
Drug: Nebulised hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised hypertonic saline (administered 38.7%–74.7% of the time in Ward A and Ward B)
Trial: 28510350
Drug: Nebulised hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised hypertonic saline (administered infrequently at 6.7% in Ward C)
Trial: 9001307
Drug: Inhaled indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled indomethacin (3 mg/m2 body surface area)
Trial: 8515850
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg i.m. every 6 hours)
Trial: 8515850
Drug: Buprenorphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.3 mg i.m. every 12 hours)
Trial: 2877912
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg h.s.
Trial: 30982861
Drug: Glucoraphanin-rich broccoli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucoraphanin-rich broccoli soup (300 mL weekly)
Trial: 30982861
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard broccoli soup, 300 mL weekly)
Trial: 26486855
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (Xeomin, Merz, Germany; 50 U/1 mL at each fat pad)
Trial: 26486855
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline, 1 mL at each fat pad)
Trial: 23717976
Drug: Compound Xiatianwu
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xiatianwu tablets (2 tablets each time, 3 times/day for 3 months)
Trial: 23717976
Drug: Xiatianwu group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiatianwu group (not specified dosage or duration)
Trial: 2659299
Drug: Traditional Dressing
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Dressing Treatment (TDT)
Trial: 28477375
Drug: l-tyrosine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tyrosine (150 mg kg-1)
Trial: 26134076
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (Zn sulfate 70 mg daily for 16 weeks)
Trial: 26134076
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical capsules containing wheat starch with no added Zn)
Trial: 26134076
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with Zinc supplementation (Zn sulfate 70 mg daily for 16 weeks)
Trial: 26134076
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with Placebo (identical capsules containing wheat starch with no added Zn)
Trial: 23343453
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics other than clozapine (NTR group)
Trial: 16920550
Drug: Acetaminophen-codeine
RxNorm normalized name: acetaminophen-codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen-codeine
Trial: 1587959
Drug: bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (400 mg daily)
Trial: 1587959
Drug: simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (20 mg daily)
Trial: 27716422
Drug: YXBCM01 granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YXBCM01 granule 5.5 g twice daily for 12 weeks
Trial: 27716422
Drug: Placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules 5.5 g twice daily for 12 weeks
Trial: 22898340
Drug: Cardiac shock
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac shock wave therapy (CSWT) performed 3 times within 3 months (Group A, n = 20)
Trial: 22898340
Drug: Cardiac shock
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac shock wave therapy (CSWT) performed 3 sessions/week for 1 month (Group B, n = 21)
Trial: 22898340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 14) received only medical therapy
Trial: 18060588
Drug: 750 mL
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mL orange juice (containing 0.545 g PB)